ECSP21082195A - Formas sólidas de un inhibidor de glyt1 - Google Patents

Formas sólidas de un inhibidor de glyt1

Info

Publication number
ECSP21082195A
ECSP21082195A ECSENADI202182195A ECDI202182195A ECSP21082195A EC SP21082195 A ECSP21082195 A EC SP21082195A EC SENADI202182195 A ECSENADI202182195 A EC SENADI202182195A EC DI202182195 A ECDI202182195 A EC DI202182195A EC SP21082195 A ECSP21082195 A EC SP21082195A
Authority
EC
Ecuador
Prior art keywords
solid forms
inhibitor
glyt1 inhibitor
glyt1
glycine transporter
Prior art date
Application number
ECSENADI202182195A
Other languages
English (en)
Inventor
Peter Sieger
Joe Ju Gao
Bing-Shiou Yang
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP21082195A publication Critical patent/ECSP21082195A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se divulgan formas sólidas de un inhibidor del transportador de glicina-1 (GlyT1). La invención también se refiere a métodos para fabricar estas formas sólidas, composiciones farmacéuticas que comprenden estas formas sólidas y su uso para afecciones médicas que responden al tratamiento con un inhibidor del transportador de glicina-1.
ECSENADI202182195A 2019-05-01 2021-11-17 Formas sólidas de un inhibidor de glyt1 ECSP21082195A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962841401P 2019-05-01 2019-05-01

Publications (1)

Publication Number Publication Date
ECSP21082195A true ECSP21082195A (es) 2021-12-30

Family

ID=70740812

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202182195A ECSP21082195A (es) 2019-05-01 2021-11-17 Formas sólidas de un inhibidor de glyt1

Country Status (23)

Country Link
US (2) US11447474B2 (es)
EP (1) EP3962911A1 (es)
JP (1) JP2022530630A (es)
KR (1) KR20220004174A (es)
CN (1) CN113784966A (es)
AR (1) AR118839A1 (es)
AU (1) AU2020266566A1 (es)
BR (1) BR112021020883A2 (es)
CA (1) CA3138288A1 (es)
CL (1) CL2021002837A1 (es)
CO (1) CO2021014260A2 (es)
CR (1) CR20210545A (es)
DO (1) DOP2021000224A (es)
EA (1) EA202192925A1 (es)
EC (1) ECSP21082195A (es)
IL (1) IL287630A (es)
JO (1) JOP20210295A1 (es)
MA (1) MA55801A (es)
MX (1) MX2021013341A (es)
PE (1) PE20212263A1 (es)
SG (1) SG11202111972YA (es)
TW (1) TW202106680A (es)
WO (1) WO2020223419A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7930336B2 (en) 2006-12-05 2011-04-19 Altera Corporation Large multiplier for programmable logic device
JP2023509792A (ja) 2020-01-09 2023-03-09 ディスク・メディシン・インコーポレイテッド グリシン輸送阻害剤を用いて骨髄性プロトポルフィリン症、ｘ連鎖プロトポルフィリン症または先天性赤血球生成性ポルフィリン症を処置する方法
CA3188340A1 (en) * 2020-08-13 2022-02-17 Boehringer Ingelheim International Gmbh Treatment of cognitive impairement associated with schizophrenia
WO2022078927A1 (en) 2020-10-13 2022-04-21 Boehringer Ingelheim International Gmbh Process of reworking

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL65843A (en) * 1977-08-11 1986-12-31 American Cyanamid Co Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type
DK1680124T3 (en) * 2003-10-14 2017-08-21 Pfizer Prod Inc Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
CN102256975A (zh) * 2008-12-04 2011-11-23 赛诺菲 氮杂二环-三氟甲基苯甲酰胺衍生物的新的多晶型形式
BRPI0923878A2 (pt) * 2008-12-29 2015-07-28 Univ Vanderbilt Inibidores de giyt1 bicíclicos 3.1.0 e métodos de produção e uso dos mesmos.
US9012489B2 (en) 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
MX2019012808A (es) * 2017-04-27 2022-02-21 Takeda Pharmaceuticals Co Compuesto heterociclico.

Also Published As

Publication number Publication date
AR118839A1 (es) 2021-11-03
MX2021013341A (es) 2021-11-17
MA55801A (fr) 2022-03-09
US11447474B2 (en) 2022-09-20
TW202106680A (zh) 2021-02-16
EA202192925A1 (ru) 2022-03-23
BR112021020883A2 (pt) 2022-04-19
CO2021014260A2 (es) 2021-10-29
AU2020266566A1 (en) 2021-11-11
US20200347041A1 (en) 2020-11-05
JP2022530630A (ja) 2022-06-30
CR20210545A (es) 2021-12-23
CA3138288A1 (en) 2020-11-05
WO2020223419A1 (en) 2020-11-05
EP3962911A1 (en) 2022-03-09
KR20220004174A (ko) 2022-01-11
CN113784966A (zh) 2021-12-10
PE20212263A1 (es) 2021-11-29
SG11202111972YA (en) 2021-11-29
IL287630A (en) 2021-12-01
CL2021002837A1 (es) 2022-07-29
US20220332710A1 (en) 2022-10-20
JOP20210295A1 (ar) 2023-01-30
DOP2021000224A (es) 2021-12-15

Similar Documents

Publication Publication Date Title
ECSP21082195A (es) Formas sólidas de un inhibidor de glyt1
CO2021005987A2 (es) Compuestos de anillo fusionado
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
CO2020009997A2 (es) Composiciones sólidas que comprenden un agonista de glp-1, una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante
CO2021001893A2 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
CL2021001430A1 (es) Composiciones de glp-1 y sus usos. (divisional de solicitud 202000422)
CR20170600A (es) Anticuerpos del factor x1 y métodos de uso
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
AR119389A1 (es) Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
CL2021002503A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251)
AR101742A1 (es) Agonista del receptor de calcitonina y amilina
CL2020002597A1 (es) Métodos para preparar composiciones proteicas estables
BR112018014540A2 (pt) formulações/composições compreendendo inibidor de btk
CO2021005915A2 (es) Composiciones estables de semaglutida y usos de las mismas
MX2020012800A (es) Cannabinoides y usos de los mismos.
CO2017008426A2 (es) Ácido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4- [(5-metiloxazol-2-carbonil)amino]pentanoico
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
PE20180691A1 (es) Variantes de il-37
EA201992168A1 (ru) Аналоги деутетрабеназина, их получение и применение
BR112017018618A2 (pt) odorizante de osmanthus
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
EA201792093A1 (ru) 2-тиопиримидиноны
EA202192149A1 (ru) Способ получения растительных материалов со сниженной вариабельностью